These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18675616)

  • 1. Educating patients about lifestyle modifications for prostate health.
    Moyad MA; Lowe FC
    Am J Med; 2008 Aug; 121(8 Suppl 2):S34-42. PubMed ID: 18675616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifestyle changes to prevent BPH: heart healthy = prostate healthy.
    Moyad MA
    Urol Nurs; 2003 Dec; 23(6):439-41. PubMed ID: 14725161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of exercise and the risk of benign prostatic hyperplasia.
    Sea J; Poon KS; McVary KT
    Phys Sportsmed; 2009 Dec; 37(4):75-83. PubMed ID: 20048544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifestyle recommendations to prevent prostate cancer, part II: time to redirect our attention?
    Moyad MA; Carroll PR
    Urol Clin North Am; 2004 May; 31(2):301-11. PubMed ID: 15123409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benign prostatic hyperplasia: does lifestyle play a role?
    Barnard RJ; Aronson WJ
    Phys Sportsmed; 2009 Dec; 37(4):141-6. PubMed ID: 20048551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benign prostatic hyperplasia. A review of diagnostic and treatment options.
    Pfeiffer GM; Giacomarra M
    Adv Nurse Pract; 1999 Apr; 7(4):31-6; quiz 37-8. PubMed ID: 10382383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alcohol consumption decreases risk of BPH.
    Rees J
    Practitioner; 2009 Dec; 253(1724):5, 3. PubMed ID: 20120825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifestyle change for coronary artery disease. What to tell patients.
    O'Keefe JH; Nelson J; Harris WS
    Postgrad Med; 1996 Feb; 99(2):89-92, 95-6, 102-6. PubMed ID: 8632976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving therapeutic outcomes in BPH through diagnosis, treatment and patient compliance.
    DeCastro J; Stone B
    Am J Med; 2008 Aug; 121(8 Suppl 2):S27-33. PubMed ID: 18675614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifestyle recommendations to prevent prostate cancer, part I: time to redirect our attention?
    Moyad MA; Carroll PR
    Urol Clin North Am; 2004 May; 31(2):289-300. PubMed ID: 15123408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors.
    St George A; Bauman A; Johnston A; Farrell G; Chey T; George J
    J Gastroenterol Hepatol; 2009 Mar; 24(3):399-407. PubMed ID: 19067776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Knowledge of cardiovascular risk factors and recommended lifestyle modifications in patients after an acute coronary syndrome. The influence of short-term, stationary rehabilitation. Preliminary results].
    Deskur-Smielecka E; Borowicz-Bieńkowska S; Przywarska I; Brychcy A; Dylewicz P
    Kardiol Pol; 2008 Feb; 66(2):230-2. PubMed ID: 18344166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease.
    Levy P
    Postgrad Med; 2009 May; 121(3 Suppl 1):7-12. PubMed ID: 19494472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethnic differences in cardiovascular disease risk factors and diabetes status for Pacific ethnic groups and Europeans in the Diabetes Heart and Health Survey (DHAH) 2002-2003, Auckland New Zealand.
    Sundborn G; Metcalf PA; Gentles D; Scragg RK; Schaaf D; Dyall L; Black P; Jackson R
    N Z Med J; 2008 Sep; 121(1281):28-39. PubMed ID: 18797481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Watchful waiting in benign prostatic hyperplasia.
    Wiygul J; Babayan RK
    Curr Opin Urol; 2009 Jan; 19(1):3-6. PubMed ID: 19057209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review.
    Alcaraz A; Hammerer P; Tubaro A; Schröder FH; Castro R
    Eur Urol; 2009 Apr; 55(4):864-73. PubMed ID: 19027219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.